biostudies-literatureUnknown15Rahal S<h4>Background</h4>Anthracycline-based adjuvant chemotherapy improves survival in patients with high-risk node-negative breast cancer (BC). In this setting, prognostic factors predicting for treatment failure might help selecting among the different available cytotoxic combinations.<h4>Methods</h4>Between 1998 and 2008, 757 consecutive patients with node-negative BC treated in our institution with adjuvant FEC (5FU, epirubicin, cyclophosphamide) chemotherapy were identified. Data collection included demographic, clinico-pathological characteristics and treatment information. Molecular subtypes were derived from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status and Scarff-Bloom-Richardson (SBR) grade. Disease-free survival (DFS), distBMC cancer697https://www.ebi.ac.uk/biostudies/studies/S-EPMC4607139biostudies-literatureImmunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.PMC4607139Resbeut MViens PLambaudie EHouvenaeghel GBoher JMThomassin-Piana JGoncalves ACharafe-Jauffret EBertucci FTarpin CExtra JMTallet ASabatier RLaborde LRahal SfalseImmunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.<h4>Background</h4>Anthracycline-based adjuvant chemotherapy improves survival in patients with high-risk node-negative breast cancer (BC). In this setting, prognostic factors predicting for treatment failure might help selecting among the different available cytotoxic combinations.<h4>Methods</h4>Between 1998 and 2008, 757 consecutive patients with node-negative BC treated in our institution with adjuvant FEC (5FU, epirubicin, cyclophosphamide) chemotherapy were identified. Data collection included demographic, clinico-pathological characteristics and treatment information. Molecular subtypes were derived from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status and Scarff-Bloom-Richardson (SBR) grade. Disease-free survival (DFS), dist2015-01-01T00:00:00Z2015 Oct2026-07-15T16:27:59.289Z2026-07-07T03:07:55.804ZS-EPMC46071392646689310.1186/s12885-015-1746-3